

What is claimed is:

1. A method of treating a lung condition in a primate exhibiting symptoms of cystic fibrosis, said method comprising administering to the respiratory system of said primate an effective amount of H_2O_2 .
2. The method of Claim 1, wherein said administering is by inhalation of H_2O_2 .
3. The method of Claim 1, wherein said administering is a formulation which produces H_2O_2 in said respiratory system.
4. The method of Claim 1, wherein said lung condition comprises infection with a:
 - a) bacterium, including Staphylococcus aureus, Pseudomonas aeruginosa, or Burkholderia cepacia;
 - b) fungus; or
 - c) virus.
5. The method of Claim 1, wherein said administering is in combination with:
 - a) administering a peroxidase; or
 - b) administering thiocyanate.
6. The method of Claim 1, wherein said administering is in combination with a treatment for a lung condition, including a lung infection or cystic fibrosis.
7. The method of Claim 6, wherein said additional treatment comprises administering an:
 - a) an antibiotic;
 - b) anti-fungal; or
 - c) anti-viral.

8. The method of Claim 6, wherein said additional treatment comprises:

- a) administering an enzyme, including a depolymerase; or
- b) an airway clearance technique or physical therapy,
5 including breathing exercises, postural drainage, chest percussion, vibration, or assisted coughing.

9. The method of Claim 1, wherein said H_2O_2 is:

- a) at a concentration between 10^{-7} M and 10^{-4} M in the
10 lung fluid; or
- b) is administered between once in a week to hourly.

10. A method of treating a lung infection in a mammal, said method comprising administering to the respiratory system of
15 said mammal an effective amount of H_2O_2 .

11. The method of Claim 10, wherein said administering is by inhalation of H_2O_2 .

20 12. The method of Claim 10, wherein said administering is a formulation which produces H_2O_2 in said respiratory system.

13. The method of Claim 10, wherein said lung infection comprises a:

- 25 a) bacterium, including Staphylococcus aureus, Pseudomonas aeruginosa, or Burkholderia cepacia;
- b) fungus; or
- c) virus.

30 14. The method of Claim 10, wherein said administering is in combination with:

- a) peroxidase; or
- b) thiocyanate.

15. The method of Claim 10, wherein said administering is in combination with an additional treatment for a lung condition, including a lung infection or cystic fibrosis.

5 16. The method of Claim 15, wherein said additional treatment comprises administering an:

- a) antibiotic;
- b) anti-fungal; or
- c) anti-viral.

10

17. The method of Claim 15, wherein said additional treatment comprises:

- a) administering an enzyme, including a depolymerase; or
- b) an airway clearance technique or physical therapy,
- 15 including breathing exercises, postural drainage, chest percussion, vibration, or assisted coughing.

18. The method of Claim 10, wherein said H_2O_2 is:

- a) at a concentration between 10^{-7} M and 10^{-4} M in the
- 20 lung fluid; or
- b) is administered between once in a week to hourly.

19. An inhaler comprising:

- a) hydrogen peroxide;
- 25 b) a peroxidase; or
- c) thiocyanate.

20. The inhaler of Claim 19, further comprising an antibiotic, an anti-fungal, or an anti-vial.